PRESS: BioSpace - Forge Biologics

PRESS: BioSpace

Ohio-based startup Forge Biologics closed a $40 million Series A financing roundthat will be used to expand manufacturing capabilities and support the clinical development of a gene therapy program for rare diseases, including the typically fatal Krabbe disease.

Forge Biologics is a viral vector contract development manufacturing organization (CDMO) and therapeutics developer. The company plans to use proceeds from the funding round to expand its adeno-associated virus (AAV) manufacturing capabilities, as well as its gene therapy pipeline. Its lead program is FBX-101a novel AAV and umbilical cord transplant combination approach to treat infantile Krabbe disease, a devastating neurodegenerative disorder. Krabbe disease has a predicted incidence of about 1 in 12,000 people in the U.S. with symptoms developing in babies and rapidly progressing to death by age two. Forge anticipates FBX-101 will enter the clinic later this year.

Read In Full:

https://www.biospace.com/article/forge-biologics-launches-with-40-million-to-manufacture-and-develop-gene-therapies/

0/5 (0 Reviews)